Threshold Pharmaceuticals, Inc., based in South San Francisco,
California, is a research-driven biotechnology company dedicated to the discovery and development of tumor targeted therapies to improve the lives of patients with cancer.
- February 24, 2015
- Threshold Pharmaceuticals Announces Presentation and Webcast at the 2015 Cowen Health Care Conference
- February 12, 2015
- Threshold Pharmaceuticals Announces Pricing of $30 Million Offering of Common Stock and Warrants
- December 6, 2014
- Encouraging Initial Data From Ongoing Phase 1/2 Trial of TH-302 Plus Bortezomib (Velcade(R)) Plus Dexamethasone ("TBorD") in Patients With Relapsed/Refractory Multiple Myeloma Presented at ASH Annual Meeting